Repost of mine from that other Board Best to the
Post# of 72440
Posted On: 01/07/2016 9:26:41 PM
Repost of mine from that other Board
Best to the Hangout crew
//
Research Topic: "Human tumor-derived p53 mutants: a growing family of oncoproteins" (Nov/Dec 2015)
V in depth overview. 5-part series. Full access. Quite the Lit Pack. Studies for you and frrol esp to chew on, digest and then spit back out to the rest of us in a more digestible format.
http://journal.frontiersin.org/researchtopic/...coproteins
Unless I missed it in my quick scan, Kevetrin went unmentioned -- under the radar still it seems. Argh. Grrr. Fetch. Still hoping something good is brewing in Beverley on the Onc front.
In the meantime, nearer-term, on with Brilacidin and Prurisol, the former getting closer and closer to market.
Looking fwd to remotely viewing next week's update and wink-wink NoRetreat's detailed recap to follow, thoughts on his QT w/ Team CTIX.
(Btw, I sent the p53 series to CTIX for Obv reasons in case they hadn't seen)
Best to all. I'm expecting a solid turnaround in 2016. Been buying.
///
Articles
1."Mutant p53: One, No One, and One Hundred Thousand"
Dawid Walerych, Kamil Lisek and Giannino Del Sal
Mini ReviewEncoded by the mutated variants of the TP53 tumor suppressor gene, mutant p53 proteins are getting an increased experimental support as active oncoproteins promoting tumor growth and metastasis. p53 missense mutant proteins are losing their wild-type ...
Published on 21 December 2015
Front. Oncol. doi: 10.3389/fonc.2015.00289
286 views 1 shares
2. "Targeting Oncogenic Mutant p53 for Cancer Therapy"
Alejandro Parrales and Tomoo Iwakuma
ReviewAmong genetic alterations in human cancers, mutations in the tumor suppressor p53 gene are the most common, occurring in over 50% of human cancers. The majority of p53 mutations are missense mutations and result in the accumulation of dysfunctional ...
Published on 21 December 2015
Front. Oncol. doi: 10.3389/fonc.2015.00288
307 views
3."Regulation of Mutant p53 Protein Expression"
Reshma Vijayakumaran, Kah Hin Tan, Panimaya Jeffreena Miranda, Sue Hauptand Ygal Haupt
Mini ReviewFor several decades p53 has been detected in cancer biopsies by virtue of its high protein expression level and considered indicative of mutation. Surprisingly, however, mouse genetic studies revealed that mutant p53 is inherently labile, similar to ...
Published on 17 December 2015
Front. Oncol. doi: 10.3389/fonc.2015.00284
219 views
4. "The Contrived Mutant p53 Oncogene?–?Beyond Loss of Functions"
Kanaga Sabapathy
ReviewMutations in p53 are almost synonymous with cancer - be it susceptibility to the disease or response to treatment - and therefore, are a critical determinant of overall survival. As most of these mutations occur in the DNA-binding domain of p53, ...
Published on 10 December 2015
Front. Oncol. doi: 10.3389/fonc.2015.00276
305 views
5. "Mutant p53: Multiple Mechanisms Define Biologic Activity in Cancer"
Michael Paul Kim, Yun Zhang and Guillermina Lozano
ReviewThe functional importance of p53 as a tumor suppressor gene is evident through its pervasiveness in cancer biology. The p53 gene is the most commonly altered gene in human cancer; however, not all genetic alterations are biologically equivalent. The ...
Published on 11 November 2015
Front. Oncol. doi: 10.3389/fonc.2015.00249
770 views 1 shares
Best to the Hangout crew
//
Research Topic: "Human tumor-derived p53 mutants: a growing family of oncoproteins" (Nov/Dec 2015)
V in depth overview. 5-part series. Full access. Quite the Lit Pack. Studies for you and frrol esp to chew on, digest and then spit back out to the rest of us in a more digestible format.
http://journal.frontiersin.org/researchtopic/...coproteins
Unless I missed it in my quick scan, Kevetrin went unmentioned -- under the radar still it seems. Argh. Grrr. Fetch. Still hoping something good is brewing in Beverley on the Onc front.
In the meantime, nearer-term, on with Brilacidin and Prurisol, the former getting closer and closer to market.
Looking fwd to remotely viewing next week's update and wink-wink NoRetreat's detailed recap to follow, thoughts on his QT w/ Team CTIX.
(Btw, I sent the p53 series to CTIX for Obv reasons in case they hadn't seen)
Best to all. I'm expecting a solid turnaround in 2016. Been buying.
///
Articles
1."Mutant p53: One, No One, and One Hundred Thousand"
Dawid Walerych, Kamil Lisek and Giannino Del Sal
Mini ReviewEncoded by the mutated variants of the TP53 tumor suppressor gene, mutant p53 proteins are getting an increased experimental support as active oncoproteins promoting tumor growth and metastasis. p53 missense mutant proteins are losing their wild-type ...
Published on 21 December 2015
Front. Oncol. doi: 10.3389/fonc.2015.00289
286 views 1 shares
2. "Targeting Oncogenic Mutant p53 for Cancer Therapy"
Alejandro Parrales and Tomoo Iwakuma
ReviewAmong genetic alterations in human cancers, mutations in the tumor suppressor p53 gene are the most common, occurring in over 50% of human cancers. The majority of p53 mutations are missense mutations and result in the accumulation of dysfunctional ...
Published on 21 December 2015
Front. Oncol. doi: 10.3389/fonc.2015.00288
307 views
3."Regulation of Mutant p53 Protein Expression"
Reshma Vijayakumaran, Kah Hin Tan, Panimaya Jeffreena Miranda, Sue Hauptand Ygal Haupt
Mini ReviewFor several decades p53 has been detected in cancer biopsies by virtue of its high protein expression level and considered indicative of mutation. Surprisingly, however, mouse genetic studies revealed that mutant p53 is inherently labile, similar to ...
Published on 17 December 2015
Front. Oncol. doi: 10.3389/fonc.2015.00284
219 views
4. "The Contrived Mutant p53 Oncogene?–?Beyond Loss of Functions"
Kanaga Sabapathy
ReviewMutations in p53 are almost synonymous with cancer - be it susceptibility to the disease or response to treatment - and therefore, are a critical determinant of overall survival. As most of these mutations occur in the DNA-binding domain of p53, ...
Published on 10 December 2015
Front. Oncol. doi: 10.3389/fonc.2015.00276
305 views
5. "Mutant p53: Multiple Mechanisms Define Biologic Activity in Cancer"
Michael Paul Kim, Yun Zhang and Guillermina Lozano
ReviewThe functional importance of p53 as a tumor suppressor gene is evident through its pervasiveness in cancer biology. The p53 gene is the most commonly altered gene in human cancer; however, not all genetic alterations are biologically equivalent. The ...
Published on 11 November 2015
Front. Oncol. doi: 10.3389/fonc.2015.00249
770 views 1 shares
(0)
(0)Innovation Pharmaceuticals Inc (IPIX) Stock Research Links
Scroll down for more posts ▼